Neurens NNZ-2566 Successful in Phase 2 Clinical Trial for Rett Syndrome. These are exciting times for Rett Syndrome. The results will enable engagement with the FDA on the further development of NNZ-2566. To date Rettsyndrome.org has invested over $1 million dollars to conduct this trial and the Natural History Data it was built on. - Steven Kaminsky, PH.D., Chief Science Officer, Rettsyndrome.org
Posted on: Wed, 07 Jan 2015 20:13:50 +0000